Literature DB >> 15302876

A natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function.

Carola Grinninger1, Wengang Wang, Kaveh Bastani Oskoui, Julia K Voice, Edward J Goetzl.   

Abstract

The vasoactive intestinal peptide (VIP) and its G protein-coupled receptors VPAC1 and VPAC2 prominently mediate diverse physiological functions in the neural, endocrine, and immune systems. A deletion variant of mouse VPAC2 has been identified in immune cells that lacks amino acids 367-380 at the carboxyl-terminal end of the seventh transmembrane domain. When expressed at equivalent levels in a human Jurkat T cell line, which has very low endogenous expression of human VPAC1 and VPAC2, wild-type and deletion-variant VPAC2 bound the same amount of 125I-VIP with similar affinity. Unlike wild-type VPAC2, however, deletion-variant VPAC2 did not transduce VIP-elicited increases in intracellular concentration of cyclic AMP, chemotaxis, or suppression of generation of interleukin-2. Natural deletion of part of the last transmembrane domain of VPAC2 thus abrogates signaling functions without apparent alterations of expression or ligand binding. Copyright 2004 American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302876     DOI: 10.1074/jbc.C400332200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  The delta e13 isoform of the calcitonin receptor forms a six-transmembrane domain receptor with dominant-negative effects on receptor surface expression and signaling.

Authors:  Thomas Seck; Maria Pellegrini; Ana Maria Florea; Veronique Grignoux; Roland Baron; Dale F Mierke; William C Horne
Journal:  Mol Endocrinol       Date:  2005-04-28

Review 2.  Alternative splicing of G protein-coupled receptors: physiology and pathophysiology.

Authors:  Danijela Markovic; R A John Challiss
Journal:  Cell Mol Life Sci       Date:  2009-07-23       Impact factor: 9.261

Review 3.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

4.  Functional splice variants of the type II G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide in mouse and human lymphocytes.

Authors:  Allison L Miller; Deepti Verma; Carola Grinninger; Mei-Chuan Huang; Edward J Goetzl
Journal:  Ann N Y Acad Sci       Date:  2006-07       Impact factor: 5.691

5.  Differential signaling of T cell generation of IL-4 by wild-type and short-deletion variant of type 2 G protein-coupled receptor for vasoactive intestinal peptide (VPAC2).

Authors:  Mei-Chuan Huang; Allison L Miller; Wengang Wang; Yvonne Kong; Sudhir Paul; Edward J Goetzl
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

Review 6.  VIP-induced neuroprotection of the developing brain.

Authors:  Sandrine Passemard; Paulina Sokolowska; Leslie Schwendimann; Pierre Gressens
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  Molecular cloning and characterization of two pig vasoactive intestinal polypeptide receptors (VPAC1-R and VPAC2-R).

Authors:  Xiaping He; Fengyan Meng; Yajun Wang; Juan Li
Journal:  DNA Cell Biol       Date:  2014-02-12       Impact factor: 3.311

Review 8.  Emerging neuropeptide targets in inflammation: NPY and VIP.

Authors:  Bindu Chandrasekharan; Behtash Ghazi Nezami; Shanthi Srinivasan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-28       Impact factor: 4.052

9.  A naturally occurring isoform inhibits parathyroid hormone receptor trafficking and signaling.

Authors:  Verónica Alonso; Juan A Ardura; Bin Wang; W Bruce Sneddon; Peter A Friedman
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

10.  Characterisation of the mouse vasoactive intestinal peptide receptor type 2 gene, Vipr2, and identification of a polymorphic LINE-1-like sequence that confers altered promoter activity.

Authors:  G Steel; E M Lutz
Journal:  J Neuroendocrinol       Date:  2007-01       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.